{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:07:28Z","timestamp":1759410448935},"reference-count":67,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T00:00:00Z","timestamp":1285027200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0012891","type":"journal-article","created":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T20:06:59Z","timestamp":1285099619000},"page":"e12891","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["A Tonsillar PolyICLC\/AT-2 SIV Therapeutic Vaccine Maintains Low Viremia Following Antiretroviral Therapy Cessation"],"prefix":"10.1371","volume":"5","author":[{"given":"Panagiotis","family":"Vagenas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meropi","family":"Aravantinou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vennansha G.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Jasny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Piatak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey D.","family":"Lifson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres M.","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agegnehu","family":"Gettie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Robbiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2010,9,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/jama.283.3.381","article-title":"Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.","volume":"283","author":"CC Carpenter","year":"2000","journal-title":"Jama"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1136\/bmj.332.7556.1489","article-title":"Antiretroviral treatment of HIV infected adults.","volume":"332","author":"SG Deeks","year":"2006","journal-title":"Bmj"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.antiviral.2009.10.007","article-title":"Current status and challenges of antiretroviral research and therapy.","volume":"85","author":"JA Este","year":"2010","journal-title":"Antiviral Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1086\/432916","article-title":"Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.","volume":"192","author":"AM Wensing","year":"2005","journal-title":"J Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy.","volume":"356","author":"A Carr","year":"2000","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/342559","article-title":"Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination.","volume":"186","author":"M Markowitz","year":"2002","journal-title":"J Infect Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1086\/432002","article-title":"Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.","volume":"192","author":"S Kinloch-de Loes","year":"2005","journal-title":"J Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1476-8518-5-6","article-title":"A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy.","volume":"5","author":"GA Hardy","year":"2007","journal-title":"J Immune Based Ther Vaccines"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/QAI.0b013e3181b880f3","article-title":"Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.","volume":"52","author":"P Vagenas","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm806","article-title":"Therapeutic dendritic-cell vaccine for simian AIDS.","volume":"9","author":"W Lu","year":"2003","journal-title":"Nat Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1128\/JVI.72.10.7992-8001.1998","article-title":"Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.","volume":"72","author":"JL Rossio","year":"1998","journal-title":"J Virol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1034\/j.1600-0684.2002.02007.x","article-title":"Whole inactivated SIV virion vaccines with functional envelope glycoproteins: Safety, immunogenicity, and activity against intrarectal challenge.","volume":"31","author":"JD Lifson","year":"2002","journal-title":"J Med Primatol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2174\/1566524033479889","article-title":"Sites, mechanism of action and lack of reversibility of primate lentivirus inactivation by preferential covalent modification of virion internal proteins.","volume":"3","author":"E Chertova","year":"2003","journal-title":"Current Molecular Medicine"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1128\/JVI.76.6.2936-2951.2002","article-title":"Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): Differential intracellular fate of virions in mature and immature DCs.","volume":"76","author":"I Frank","year":"2002","journal-title":"J Virol"},{"key":"ref15","first-page":"7","article-title":"Presentation of exogenous whole inactivated simian immunodeficiency virus by mature dendritic cells induces CD4+ and CD8+ T cell responses.","volume":"34","author":"I Frank","year":"2003","journal-title":"J AIDS"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1147","article-title":"Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.","volume":"10","author":"W Lu","year":"2004","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/eji.200324032","article-title":"Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.","volume":"34","author":"J Vollmer","year":"2004","journal-title":"Eur J Immunol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1189\/jlb.1202630","article-title":"Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions.","volume":"73","author":"JD Marshall","year":"2003","journal-title":"J Leuk Biol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.4049\/jimmunol.173.3.1647","article-title":"CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells.","volume":"173","author":"N Teleshova","year":"2004","journal-title":"J Immunol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1189\/jlb.0205084","article-title":"CpG-C ISS-ODN activation of blood-derived B cells from healthy and chronic immunodeficiency virus-infected macaques.","volume":"79","author":"N Teleshova","year":"2006","journal-title":"J Leuk Biol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.4049\/jimmunol.177.12.8531","article-title":"Local and systemic effects of intranodally injected CpG-C ISS-ODNs in macaques.","volume":"177","author":"N Teleshova","year":"2006","journal-title":"J Immunol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1128\/JVI.00023-08","article-title":"Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G.","volume":"83","author":"S Trapp","year":"2009","journal-title":"J Virol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1073\/pnas.0711976105","article-title":"The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine.","volume":"105","author":"C Trumpfheller","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1172\/JCI39293","article-title":"Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.","volume":"120","author":"Q Zhu","year":"2010","journal-title":"J Clin Invest"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e1000373","DOI":"10.1371\/journal.ppat.1000373","article-title":"Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques.","volume":"5","author":"C Stahl-Hennig","year":"2009","journal-title":"PLoS Pathog"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1084\/jem.20090247","article-title":"Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.","volume":"206","author":"MP Longhi","year":"2009","journal-title":"J Exp Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2174\/138161209787846775","article-title":"Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses.","volume":"15","author":"JP Wong","year":"2009","journal-title":"Curr Pharm Des"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.vaccine.2009.01.048","article-title":"Activation of toll-like receptor signaling pathway for protection against influenza virus infection.","volume":"27","author":"JP Wong","year":"2009","journal-title":"Vaccine"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11060-008-9693-3","article-title":"A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).","volume":"91","author":"N Butowski","year":"2009","journal-title":"J Neurooncol"},{"key":"ref30"},{"key":"ref31","first-page":"1","article-title":"Guide for the Care and Use of Laboratory Animals."},{"key":"ref32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0684.2005.00128.x","article-title":"Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS.","volume":"34","author":"AN Cline","year":"2005","journal-title":"J Med Primatol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1089\/088922299309739","article-title":"Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression.","volume":"15","author":"SM Smith","year":"1999","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/JVI.01672-08","article-title":"Correlation of vaccine-elicited systemic and mucosal non-neutralizing antibody activities with reduced acute viremia following intrarectal SIVmac251 challenge of rhesus macaques.","volume":"83","author":"R Hidajat","year":"2009","journal-title":"J Virol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ymeth.2005.12.004","article-title":"Intracellular cytokine staining for the characterization and quantitation of antigen-specific T lymphocyte responses.","volume":"38","author":"MC Gauduin","year":"2006","journal-title":"Methods"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/aid.1994.10.351","article-title":"Mucosal infection of neonatal rhesus monkeys with cell-free SIV.","volume":"10","author":"TW Baba","year":"1994","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2741\/2215","article-title":"A single vaccination with attenuated SIVmac 239 via the tonsillar route confers partial protection against challenge with SIVmac 251 at a distant mucosal site, the rectum.","volume":"12","author":"C Stahl-Hennig","year":"2007","journal-title":"Front Biosci"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.virol.2007.02.041","article-title":"Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.","volume":"366","author":"PL Earl","year":"2007","journal-title":"Virology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"11467","DOI":"10.1128\/JVI.01143-08","article-title":"Antiretroviral therapy prior to acute viral replication preserves CD4 T cells in the periphery but not in rectal mucosa during acute simian immunodeficiency virus infection.","volume":"82","author":"M Kader","year":"2008","journal-title":"J Virol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"613","DOI":"10.7326\/0003-4819-128-8-199804150-00001","article-title":"Biological and virologic characteristics of primary HIV infection.","volume":"128","author":"TW Schacker","year":"1998","journal-title":"Ann Intern Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.1128\/JVI.71.10.7518-7525.1997","article-title":"Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection.","volume":"71","author":"MA Nowak","year":"1997","journal-title":"J Virol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"13288","DOI":"10.1073\/pnas.221452198","article-title":"Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.","volume":"98","author":"GM Ortiz","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1128\/CVI.00471-08","article-title":"Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine.","volume":"16","author":"Y Wang","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/JVI.63.10.4277-4284.1989","article-title":"Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus.","volume":"63","author":"CJ Miller","year":"1989","journal-title":"J Virol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1128\/JVI.77.3.2165-2173.2003","article-title":"Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus.","volume":"77","author":"JE Schmitz","year":"2003","journal-title":"J Virol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/mi.2007.5","article-title":"High frequencies of polyfunctional HIV-specific T cells are associated with preservation of mucosal CD4 T cells in bronchoalveolar lavage.","volume":"1","author":"JM Brenchley","year":"2008","journal-title":"Mucosal Immunol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1089\/aid.2006.0162","article-title":"CD25+ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ T cells in vitro.","volume":"23","author":"AL Kinter","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.4049\/jimmunol.174.7.4407","article-title":"Depletion of regulatory T cells in HIV infection is associated with immune activation.","volume":"174","author":"MP Eggena","year":"2005","journal-title":"J Immunol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"e9852","DOI":"10.1371\/journal.pone.0009852","article-title":"Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART.","volume":"5","author":"BJ Macatangay","year":"2010","journal-title":"PLoS One"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.4049\/jimmunol.0902955","article-title":"Expansion of FOXP3+ CD8 T cells with suppressive potential in colorectal mucosa following a pathogenic simian immunodeficiency virus infection correlates with diminished antiviral T cell response and viral control.","volume":"184","author":"P Nigam","year":"2010","journal-title":"J Immunol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.coi.2007.04.012","article-title":"PD-1 and its ligands in T-cell immunity.","volume":"19","author":"ME Keir","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.","volume":"11","author":"Y Ishida","year":"1992","journal-title":"Embo J"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.","volume":"443","author":"CL Day","year":"2006","journal-title":"Nature"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2007-01-069112","article-title":"SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection.","volume":"110","author":"C Petrovas","year":"2007","journal-title":"Blood"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade.","volume":"458","author":"V Velu","year":"2009","journal-title":"Nature"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"980","DOI":"10.4049\/jimmunol.182.2.980","article-title":"PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination.","volume":"182","author":"AC Finnefrock","year":"2009","journal-title":"J Immunol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4049\/jimmunol.0902781","article-title":"Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1.","volume":"184","author":"NC Salisch","year":"2010","journal-title":"J Immunol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1128\/JVI.77.4.2736-2740.2003","article-title":"Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication.","volume":"77","author":"BR Mothe","year":"2003","journal-title":"J Virol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"7763","DOI":"10.4049\/jimmunol.0900111","article-title":"Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity.","volume":"182","author":"JT Loffredo","year":"2009","journal-title":"J Immunol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1128\/JVI.80.10.5074-5077.2006","article-title":"The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication.","volume":"80","author":"LJ Yant","year":"2006","journal-title":"J Virol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1086\/315800","article-title":"Homozygosity for a conserved Mhc class II DQ-DRB haplotype is associated with rapid disease progression in simian immunodeficiency virus-infected macaques: results from a prospective study.","volume":"182","author":"U Sauermann","year":"2000","journal-title":"J Infect Dis"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/15224","article-title":"Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus env and Nef.","volume":"5","author":"DT Evans","year":"1999","journal-title":"Nat Med"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nri2636","article-title":"Monkeying around with HIV vaccines: using rhesus macaques to define \u2018gatekeepers\u2019 for clinical trials.","volume":"9","author":"DJ Shedlock","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.4049\/jimmunol.169.9.5347","article-title":"Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy.","volume":"169","author":"E Tryniszewska","year":"2002","journal-title":"J Immunol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/gt.2008.152","article-title":"Effect of therapeutic immunization using Ad5\/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy.","volume":"16","author":"M Shimada","year":"2009","journal-title":"Gene Ther"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.vaccine.2009.10.099","article-title":"Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit.","volume":"28","author":"A Valentin","year":"2010","journal-title":"Vaccine"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1089\/aid.2008.0055","article-title":"A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques.","volume":"24","author":"J zur Megede","year":"2008","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0012891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:56:28Z","timestamp":1591923388000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0012891"}},"subtitle":[],"editor":[{"given":"Douglas F.","family":"Nixon","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2010,9,21]]},"references-count":67,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2010,9,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0012891","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,21]]}}}